💰 Financial Performance

Revenue Growth by Segment

Domestic Branded Formulations (DBF) grew 10% YoY in Q2 FY26 to INR 708 Cr and 11% in H1 FY26 to INR 1,410 Cr. The International Business revenue was INR 83 Cr in Q2 FY26, a slight decline of 1% YoY, and INR 152 Cr in H1 FY26, down 4% YoY due to capacity being utilized for validation batches.

Geographic Revenue Split

India (Domestic) remains the dominant market contributing approximately 89.4% of Q2 FY26 revenue. International markets, including Africa, Asia-Pacific, Latam, and CIS/Middle East, contribute the remaining 10.6%. The company targets increasing the Regulated Markets (EU/Brazil) share to 30% of revenue by FY27.

Profitability Margins

Gross Margin stood at 74.5% in Q2 FY26 compared to 74.9% in Q2 FY25. Net Profit Margin significantly improved to 17.0% in Q2 FY26 from 13.1% in the previous year, driven by a 17% reduction in interest costs and a 51% drop in depreciation expenses.

EBITDA Margin

Consolidated EBITDA margin improved by 65 bps YoY to 36.4% in Q2 FY26 (INR 288 Cr). The DBF segment maintained a high margin of 37.6%, while the acquired Biocon business saw a turnaround with margins expanding from 19% at acquisition to 32% in Q2 FY26.

Capital Expenditure

The company has front-loaded its capex, planning to invest INR 380 to INR 400 Cr over the next three quarters. This is part of a larger INR 750 to INR 800 Cr three-year capex plan (FY26-FY28) focused on Bhopal Phase 2, Swiss Unit-3, and Levim manufacturing.

Credit Rating & Borrowing

Net debt stood at INR 2,278 Cr as of September 2025. Finance costs decreased by 16.7% YoY to INR 50 Cr in Q2 FY26. The Net Debt-to-EBITDA ratio has been reduced from 4x to 2x over the last 18 months, with a target of 1.3x by December 2026.

⚙️ Operational Drivers

Raw Materials

Specific raw material names are not explicitly listed, but the company focuses on active pharmaceutical ingredients (APIs) for chronic therapies and specialized components for Insulin and GLP-1 injectables. Manufacturing costs are being optimized by shifting the Biocon portfolio to in-house production.

Capacity Expansion

Current manufacturing spans 6 locations. Planned expansions include Bhopal Phase 2 (INR 150 Cr), Swiss Unit-3 (INR 130 Cr), and a second round of investment in Levim Lifetech (INR 100 Cr) for Diabesity pipeline and DS manufacturing.

Raw Material Costs

Gross Profit was INR 590 Cr in Q2 FY26 (74.5% of revenue). The company is pursuing a strategy of in-house manufacturing for acquired brands to reduce third-party procurement costs and expand margins by FY27.

Manufacturing Efficiency

The Biocon business turnaround is a key efficiency metric, with margins rising to 32%. In-house manufacturing for these products is expected to provide further margin expansion starting in FY27.

Logistics & Distribution

Other expenses, which include distribution and marketing, were INR 164 Cr in Q2 FY26, representing 20.7% of revenue, down from 22.2% YoY, indicating improved distribution efficiency.

📈 Strategic Growth

Expected Growth Rate

11-15%

Growth Strategy

Growth will be driven by a '50% over market' target in domestic formulations, the launch of RHI cartridges in Dec-2025, and a massive scale-up in the EU-CDMO business which has an order book of INR 700-800 Cr. The company is also expanding into high-growth therapies like GLP-1 and Oncology.

Products & Services

Branded pharmaceutical formulations in oral anti-diabetes, cardiology, dermatology, nephrology, oncology, and women's health. Specific products include Insulins, GLP-1 injectables, and RHI cartridges.

Brand Portfolio

Eris, Oaknet, Swiss Parenterals, Biocon (acquired domestic business), and Eris BioNxt.

New Products/Services

Launch of RHI cartridges starting Dec-2025 and a robust Diabesity pipeline. The EU-CDMO business is expected to be a major contributor, with revenue visibility of INR 125-150 Cr in the near term.

Market Expansion

Expanding from India into Africa, Asia-Pacific, Latam, and the CIS/Middle East, with a current strategic focus on entering the European Union through a Specialty CDMO model.

Market Share & Ranking

Eris grew at 10% in Q2 FY26, which is 30% higher than the Indian Pharmaceutical Market (IPM) growth of 7.7%. In H1, it grew 11%, which is 42% over the IPM growth of 7.4%.

Strategic Alliances

30% equity stake in Levim Lifetech (Bio) with an agreement to enhance it to 49%. Joint Venture with Levim Lifetech Private Limited.

🌍 External Factors

Industry Trends

The industry is shifting toward biologics and complex injectables. Eris is positioning itself by investing in Insulin and GLP-1 capacities, expecting regulated markets to contribute 30% of revenue by FY27, up from <2% in FY24.

Competitive Landscape

Competes with major Indian pharmaceutical players in the domestic branded market and global CDMOs in the international segment.

Competitive Moat

Eris maintains a moat through its leadership in chronic therapies (Diabetes/Cardio) and high-entry-barrier manufacturing (Injectables/Biologics). Its shift toward a Specialty CDMO model for the EU provides long-term revenue stickiness.

Macro Economic Sensitivity

The business is sensitive to the growth of the Indian Pharmaceutical Market (IPM), consistently aiming to outperform it by 50%.

Consumer Behavior

Increasing demand for advanced diabetes management (Insulins/GLP-1) is driving the company's shift toward injectable formulations.

Geopolitical Risks

Expansion into Regulated Markets (EU) and Latam (Brazil) subjects the company to stringent international regulatory inspections and trade standards.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to ANVISA (Brazil) and EU-GMP standards. The company recently received ANVISA approval for its oral liquids line and is targeting inspections for oral solids and injectables in Jan-2026.

Taxation Policy Impact

The effective tax rate was 22.2% in Q2 FY26, down from 25.1% in Q2 FY25.

Legal Contingencies

The auditor identified Purchase Price Allocation (PPA) for business combinations (acquisitions) as a Key Audit Matter, involving significant management judgment and estimates.

⚠️ Risk Analysis

Key Uncertainties

Regulatory approval delays for new products (e.g., gSaxenda) and the successful integration of large-scale acquisitions (Biocon, Swiss Parenterals) pose risks to projected EBITDA margins.

Geographic Concentration Risk

High concentration in the Indian market (~89%), though aggressively diversifying into international regulated markets.

Third Party Dependencies

The company is reducing dependency on third-party manufacturers by bringing acquired portfolios (Biocon) in-house to capture higher margins.

Technology Obsolescence Risk

Risk is mitigated by investing in cutting-edge biologic and injectable manufacturing technologies (Insulin/GLP-1).

Credit & Counterparty Risk

Trade receivables stood at INR 57.09 Cr as of March 2024, with the company maintaining internal financial controls to manage credit risk.